Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 12:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,155 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza vaccine Clear all
Completed Phase 4 Interventional

VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)

NCT03955991
View directory record Official record
Conditions
Stress
Interventions
R-CBSM, Influenza vaccine
Behavioral · Biological
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

NCT00959049
View directory record Official record
Conditions
Influenza
Interventions
CSL's Influenza Virus Vaccine (Afluria), Influenza Virus Vaccine (Fluzone)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 17 Years
Enrollment
1,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
23
States / cities
Chandler, Arizona • Harrisburg, Arkansas • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Meditation and Exercise for Prevention of Acute Respiratory Infection

NCT01057771
View directory record Official record
Conditions
Acute Respiratory Infection
Interventions
Meditation, Exercise
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Mix and Match With AS03

NCT01317758
View directory record Official record
Conditions
Influenza
Interventions
AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen
Drug · Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 12, 2026, 12:33 PM EDT
Terminated Phase 1 Interventional

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05395052
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
Interventions
FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older

NCT02464163
View directory record Official record
Conditions
Influenza
Interventions
Panblok, rHA adjuvant
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
9
States / cities
Mobile, Alabama • DeLand, Florida • Savannah, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 12, 2026, 12:33 PM EDT
Not listed No phase listed Observational

National Vaccine Adverse Event Reporting Survey and Etiology

NCT05095844
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults

NCT04896086
View directory record Official record
Conditions
Influenza, Seasonal Influenza
Interventions
VRC-GENADJ0110-AP-NV (Adjuplex), Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 12, 2026, 12:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

NCT00964821
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 12, 2026, 12:33 PM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

NCT04613206
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

NCT03895385
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

NCT06683352
View directory record Official record
Conditions
Influenza,Human, COVID-19
Interventions
Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Placebo
Biological · Combination Product · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
22
States / cities
Lake Forest, California • San Diego, California • Walnut Creek, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Not applicable Interventional

Reducing Delay in Vaccination of Children: Logistic Barriers

NCT03516682
View directory record Official record
Conditions
Communicable Disease
Interventions
Reminders
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
1 Month to 11 Months
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Promoting Altruism to Enhance Vaccine Acceptance

NCT04568590
View directory record Official record
Conditions
Vaccine Refusal
Interventions
educational intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Senescent Immunity in Elders and Vaccine Responses (SILVER)

NCT04077424
View directory record Official record
Conditions
Flu Vaccine
Interventions
Fluzone-High Dose Quadrivalent, Fluad, Flublock
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
65 Years to 125 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 12, 2026, 12:33 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age

NCT01997450
View directory record Official record
Conditions
Influenza Vaccine Effectiveness
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
4,121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
8
States / cities
Gainesville, Florida • Bloomington, Minnesota • Winston-Salem, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation

NCT02807623
View directory record Official record
Conditions
Immune System and Related Disorders
Interventions
Ibuprofen, Compound Exercise of Push-ups, oral placebo
Drug · Behavioral
Lead sponsor
Womack Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Bethesda, Maryland • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Fermented Soy Product on Cognition, Immune Status and Vaccine

NCT04866576
View directory record Official record
Conditions
Cognitive Change, Inflammation, Immune Response
Interventions
Q CAN PLUS, Placebo
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
65 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

University of Wisconsin Meditation & Exercise Cold Study

NCT01654289
View directory record Official record
Conditions
Acute Respiratory Infection
Interventions
Mindfulness Meditation, Exercise
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
30 Years to 69 Years
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine

NCT02212990
View directory record Official record
Conditions
Fever
Interventions
Acetaminophen Arm, Placebo Arm, Ibuprofen Arm
Other
Lead sponsor
Duke University
Other
Eligibility
6 Months to 47 Months
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 1 Interventional

Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

NCT02594189
View directory record Official record
Conditions
Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2
Interventions
Live recombinantly derived A/Bethesda/MM1/H3N2 virus
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

NCT00395174
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
65 Years and older
Enrollment
870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Baltimore, Maryland • Rochester, Minnesota • Shrewsbury, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

NCT03275389
View directory record Official record
Conditions
Influenza, Human
Interventions
D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 39 Years
Enrollment
470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
5
States / cities
South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 12, 2026, 12:33 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

NCT06727058
View directory record Official record
Conditions
Influenza Immunization
Interventions
Pandemic flu H5 mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
14
States / cities
La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 12, 2026, 12:33 PM EDT